CS1 (CD319) | CD molecules | IUPHAR/BPS Guide to PHARMACOLOGY

CS1 (CD319)

Target id: 2850

Nomenclature: CS1 (CD319)

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     CS1 (CD319) has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 335 1q23.1-q24.1 SLAMF7 SLAM family member 7
Mouse 1 333 1 H2 Slamf7 SLAM family member 7
Rat 1 342 13q24 Slamf7 SLAM family member 7
Previous and Unofficial Names
CRACC | CS1-L | CD2-like receptor-activating cytotoxic cells
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
elotuzumab Hs Binding 8.1 pKd 2
pKd 8.1 (Kd 8.86x10-9 M) [2]
Immunopharmacology Comments
CS1 is a member of the signalling lymphocyte activation molecule (SLAM) receptor family. CS1 is a membrane glycoprotein primarily expressed on plasma cells. Homophilic interaction (i.e. interaction with itself) of CS1 induces B cell proliferation and autocrine cytokine secretion, thus playing a role in various immune functions.

CS1 is a validated molecular target for the development of novel immunotherapeutics with the potential to treat MM, a malignant disease of plasma cells which remains incurable despite advances in treatment (such as bortezomib, lenalidomide and immunotherapies in clinical trial). Indeed, a combination therapy containing the anti-CS1 mAb elotuzumab (elotuzumab + lenalidomide + dexamethasone), was FDA approved for MM in 2015. CS1 expression is also elevated in patients with systemic lupus erythematosus (SLE) [1], suggesting that this condition may also benefit from clinical CS1-targeted inhibition.
Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   macrophage (CL:0000235)
monocyte (CL:0000576)
Immuno Cell Type:  Natural killer cells
Cell Ontology Term:   natural killer cell (CL:0000623)
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Immuno Cell Type:  B cells
Cell Ontology Term:   plasma cell (CL:0000786)
Immuno Cell Type:  T cells
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes
GO:0042267 natural killer cell mediated cytotoxicity NAS
Immuno Process:  Immune regulation
GO Annotations:  Associated to 1 GO processes
GO:0050776 regulation of immune response TAS
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes
GO:0030101 natural killer cell activation NAS
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002250 adaptive immune response IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002250 adaptive immune response IEA


Show »

1. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. (2010) Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin. Exp. Immunol., 160 (3): 348-58. [PMID:20345977]

2. Williams M, Tso JY, Landolfi NF, Powers DB, Liu G. (2010) Therapeutic use of anti-CS1 antibodies. Patent number: US7709610. Assignee: Facet Biotech Corporation. Priority date: 28/05/2003. Publication date: 04/05/2010.

How to cite this page

CD molecules: CS1 (CD319). Last modified on 15/05/2017. Accessed on 25/09/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2850.